Effect of pregnancy on scleroderma progression
- PMID: 36743807
- PMCID: PMC9896202
- DOI: 10.1177/23971983221101311
Effect of pregnancy on scleroderma progression
Abstract
Objective: To explore the trajectory of scleroderma disease activity in women who experienced a pregnancy after systemic sclerosis diagnosis compared to nulliparous women.
Methods: We analyzed data from the Canadian Scleroderma Research Group registry by identifying nulliparous women and women with ⩾1 pregnancy after systemic sclerosis diagnosis. Patient characteristics were compared between groups at registry entry. Controlling for age, smoking, and time since systemic sclerosis diagnosis, generalized estimating equations tested the effect of pregnancy on force vital capacity, diffusing capacity of the lungs for carbon monoxide, right ventricular systolic pressure, glomerular filtration rate, antibody status, active digital ulcers, physician global assessment of activity, and severity over 9 years.
Results: At registry entry, numbers of women in the nulliparous and pregnancy after systemic sclerosis diagnosis groups were 153 and 45, respectively. Corresponding numbers at 6 and 9 years were 48 and 21, and 18 and 9, respectively. The prevalence of anti-topoisomerase positivity was 18.3% in nulliparous and 12.5% in pregnancy after systemic sclerosis diagnosis. Baseline differences included mean (Standard deviation) age of diagnosis (nulliparous: 38.8 (14.0), pregnancy after systemic sclerosis diagnosis: 22.6 (6.8) years, p < 0.001), disease duration (nulliparous: 9.6 (8.9), pregnancy after systemic sclerosis diagnosis: 21.9 (9.6) years; p < 0.001), and inflammatory arthritis (nulliparous: 41 (28%), pregnancy after systemic sclerosis diagnosis: 22 (49%), p = 0.009). There were no significant differences between groups in the change of any outcomes over time.
Conclusion: Results demonstrated that having ⩾1 pregnancy after systemic sclerosis diagnosis did not appear to significantly impact long-term renal, respiratory, or global function outcomes. While this offers a hopeful message to systemic sclerosis patients planning a pregnancy, physicians and patients should remain vigilant for potential post-partum complications.
Keywords: Pregnancy; disease progression; systemic sclerosis.
© The Author(s) 2022.
Conflict of interest statement
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The CSRG is supported financially by the Canadian Institutes of Health Research (CIHR), the Scleroderma Society of Canada, Scleroderma Society of Ontario and Cure Scleroderma Foundation.
References
-
- Mayes MD, Lacey JV, Jr, Beebe-Dimmer J, et al.. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003; 48(8): 2246–2255. - PubMed
-
- Blagojevic J, AlOdhaibi K, Aly A, et al.. Pregnancy in systemic sclerosis: results of a systematic review and meta-analysis. J Rheumatol 2019; 47: 881–887. - PubMed
-
- Tincani A, Dall’Ara F, Lazzaroni MG, et al.. Pregnancy in patients with autoimmune disease: a reality in 2016. Autoimmun Rev 2016; 15(10): 975–977. - PubMed
LinkOut - more resources
Full Text Sources